Although pyoderma gangrenosum can increase your risk of death, getting treatment and seeing your care team regularly can make it possible to live a full, healthy life.

Pain as a patient-reported outcome measure during the treatment of pyoderma gangrenosum may indicate whether a patient is responding to treatment, according to a research letter published in JAMA ...

Key takeaways: Ulcerative pyoderma gangrenosum is a rare disease with no current treatment. Vilobelimab has been granted orphan drug and fast track designations by the FDA. InflaRx has initiated a ...

METHODOLOGY: To help determine whether a patient with pyoderma gangrenosum is responding to treatment, researchers used a patient global assessment (PGA) score to establish a minimal important ...

The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ: IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).

"We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum. There are currently no ...

This research is significant as Humira is the only approved treatment for Pyoderma Gangrenosum in Japan. The study tested Humira (Adalimumab), an injectable medication, on approximately 60 ...